Prognostic value of immunohistochemical expression of ZAP-70 and CD38 in chronic lymphocytic leukaemia detected on bone marrow and lymph node biopsies / Valoarea prognostică a expresiei imunohistochimice a ZAP-70 si CD38 în leucemia limfocitară cronică detectată pe biopsii osteomedulare și limfoganglionare

Open access

Abstract

Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Among useful markers in identifiyng patients with poor outcome are unmutated IgVH, ZAP-70 and CD38 expression. Both ZAP-70 and CD38 were shown to be capable of identifying aggressive CLL.

We analysed data from 35 patients diagnosed with CLL based on morphological and immunophenotypical criteria. In all cases peripheral blood immunophenotyping was performed as initial diagnostic test. Immunohistochemical expression of ZAP-70 and CD38 was evaluated on 21 cases of lymph node biopsies and 14 cases of bone marrow biopsies, performed at the time of diagnosis. In addition in-situ hybridization for EBER-1 was evaluated.

The median age of patients was 60 years and we noted a slight male predominance. The immunophenotypic criteria (C23+, CD5+, CD20+, CD10-, CD3-, cyclinD1-) for B-cell CLL were achieved in all 35 patients. We found that CLL cases showing expression of both markers (ZAP-70+CD38+ patients) are characterised by an unfavourable clinical course as compared with cases that did not show expression of markers (ZAP-70-CD38- patients). Our data showed significant differences in terms of overall survival at 5 years between the two groups. We also found statistically significant differences between patients ZAP-70-CD38- and patients with one or both positive markers (ZAP-70+ and/or CD38+).

Prognostic information given by ZAP-70 and CD38 could be used in guiding treatment decisions and they probably should be recommended to all patients with B-CLL in trying to obtain a more clear profile of the disease at the time of diagnosis.

1. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, et al. Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology Am Soc Hematol Educ Program. 2003; 153-75. DOI: 10.1182/ asheducation-2003.1.153

2. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004 Feb 15; 103(4):1202-10. DOI: 10.1182/blood-2003-07-2281

3. Siddon AJ, Rinder HM. Pathology consulatation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. Am J Clin Pathol. 2013 Jun; 139(6):708-12. DOI: 10.1309/ AJCPLIR4GZWX3XKA

4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leuke mia. Blood. 1999 Sep 15; 94(6):1848-54.

5. Hamblin TJ. Searching for surrogates for IGVH mutations in chronic lymphocytic leukemia. Leuk Res. 2011 Nov;35(11):1432-5. DOI: 10.1016/j.leukres. 2011.07.020

6. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1; 348(18):1764-75. DOI: 10.1056/NEJMoa023143

7. Wiggers TGH, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, et al. ZAP70 in B-CLL Cells Related to the Expression in NK Cells is a Surrogate Marker for Mutational Status. Cytometry Part B. 2014 Jul; 86(4):280-7. DOI: 10.1002/cyto.b.21132

8. Weiss A, Iwashima M, Irving B, van Oers NS, Kadlecek TA, Straus D, et al. Molecular and genetic insights into T cell antigen receptor signal transduction. Adv Exp Med Biol. 1994; 365:53-62. DOI: 10.1007/978-1-4899-0987-9_6

9. Weiss A, Chan AC, Iwashima M, Straus D, Irving BA. Regulation of protein tyrosine kinase activation by the T-cell antigen receptor zeta chain. Cold Spring Harb Symp Quant Biol. 1992;57:107-16. DOI: 10.1101/ SQB.1992.057.01.014

10. Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia. 2005 Jun; 19(6):1018-24. DOI: 10.1038/sj.leu.2403726

11. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi A, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia. 2006 Apr; 20(4):689-95. DOI: 10.1038/sj.leu.2404138

12. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. DOI: 10.1182/blood-2002-06-1683

13. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75. DOI:10.1056/NEJMoa023143

14. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004 Jan 10;363(9403):105-11. DOI: 10.1016/S0140-6736(03)15260-9

15. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351(9):893-01. DOI: 10.1056/NEJMoa040857

16. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007 Mar 1;109(5):2032-9. DOI: 10.1182/ blood-2006-03-011759

17. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, et al. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocyticleukemia Blood. 2014 Jul 3;124(1):42-8. DOI: 10.1182/blood-2014-02-555722

18. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003 Sep 15;102(6):2146-55. DOI: 10.1182/blood-2003-03-0989

19. Jaksic O, Paro MM, Kardum Skelin I, Kusec R, Pejsa V, Jaksic B. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood. 2004 Mar 1; 103(5):1968-9. DOI: 10.1182/blood-2003-11-3890

20. Adams RLC, Cheung C, Banh R, Saal R, Cross D, Gill D, et al. Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Cytometry B Clin Cytom. 2014 Mar; 86(2):80-90. DOI: 10.1002/cyto.b.21138

21. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004 Feb 15; 103(4):1202-10. DOI: 10.1182/blood-2003-07-2281

22. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A et al. Cd38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002 Jan; 16(1):30-5

23. Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro C, Remo A, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia. 2007 Jan; 21(1):102-9. DOI: 10.1038/sj.leu.2404458

24. Carreras J, Villamor N, Colomo L, Moreno C, Ramon y Cajal S, Crespo M, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol. 2005 Mar; 205(4):507-13. DOI: 10.1002/path.1727

25. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the mea surement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol. 2005 Aug;27(4):258-66. DOI: 10.1111/j.1365-2257.2005.00703.x

26. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006 May; 47(5):827-36. DOI: 10.1080/10428190500398856

27. Tsimberidou AM, O’Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302. DOI: 10.1002/cncr.22121

28. Petrella T, Yaziji N, Collin F, Rifle G, Morlevat F, Arnould L, et al. Implication of the Epstein-Barr virus in the progression of chronic lymphocytic leukaemia/ small lymphocytic lymphoma to Hodgkin-like lymphomas. Anticancer Res. 1997 sep-Oct; 17(5B):3907-13.

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 165 165 10
PDF Downloads 48 48 1